Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma

This analysis assessed the effect of lenalidomide on progression-free survival (PFS). Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenali...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, M A, Hussein, M, Swern, A S, Weber, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194066/
https://www.ncbi.nlm.nih.gov/pubmed/21747400
http://dx.doi.org/10.1038/leu.2011.126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194066/
https://www.ncbi.nlm.nih.gov/pubmed/21747400
http://dx.doi.org/10.1038/leu.2011.126

Ejemplares similares